Baron and Budd Recognizes UCLA-Hosted Symposium May 18 on Lung-Sparing Therapies for Malignant Pleural Mesothelioma

UCLA Oncologists Offer Discussion on Lung-Sparing Techniques in Mesothelioma Treatment.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Dallas, TX (PRWEB) April 20, 2013

The 3rd International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma will take place (MPM) on Saturday, May 18, in Santa Monica, Calif. From the standpoint of surgery, ‘lung-sparing’ refers to a procedure called Pleurectomy/Decortication (PD). Unlike the more aggressive Extrapleural Pneumonectomy (EPP) that advocates removing the lung closest to the tumor, plus part or all of the diaphragm and other diseased membranes, PD leaves both lungs intact. The premise behind is the surgery is that a patient who is equipped with both lungs will enjoy a longer, higher quality of life and better tolerate recurring treatments (http://www.cme.ucla.edu/courses/cme-download?event%5fid=2108435).

The Lung-Sparing Symposium will target experts, medical oncologists, patients and loved ones desiring to know more about the cancer. In addition to apprising audiences about the pros and cons of lung-sparing surgery, discussion will segue to respective roles of each component in multidisciplinary therapies (added therapies) including radiation, chemotherapy, daily self-injected immunotherapy and thermal/photodynamic therapy (hot or cold).

Malignant Pleural Mesothelioma is much different than other cancers. Instead of growing as a lump or node within an organ— entirely removable with an extra margin of normal tissue— mesothelioma is a thin veil of cancer cells blanketing virtually every organ and surface inside the chest cavity. Such diffused formation prevents complete removal of the malignant tumor with clearance; even hypothetically such a procedure would involve removing vital organs such as the heart, lungs, diaphragm, major vessels, and ribs. The UCLA presentation will approach treating mesothelioma as a chronic disease, such as diabetes or high blood pressure, with ongoing post-surgical tools to lessen the chance of diseased cell reformation.

Mesothelioma law firm Baron and Budd has been protecting the rights of mesothelioma patients for more than 35 years. The firm has a history of supporting mesothelioma research and advocacy and stands ready to help those who have been harmed by asbestos exposure. Visit the firm’s website to learn more about Baron and Budd’s mesothelioma lawyers. http://baronandbudd.com/areas-of-practice/mesothelioma-attorney/

About Baron & Budd

The national mesothelioma law firm of Baron & Budd, P.C. has a more than 30-year history of “Protecting What’s Right” for asbestos sufferers and their families. As one of the first law firms to successfully litigate an asbestos lawsuit, Baron & Budd continues to actively represent veterans, industry workers and others who are suffering as a result of exposure to asbestos. Baron & Budd achieved the largest mesothelioma verdict ever in the state of Texas, a $55 million verdict for an asbestos sufferer and his family in El Paso, Texas. Contact Baron and Budd at 1.866.855.1229 for additional information on mesothelioma treatments, mesothelioma cancer doctors and treatment centers and mesothelioma attorneys.


Contact

  • Amanda Theaker, Marketing
    Baron & Budd
    214.991.1051
    Email